



Corindus Vascular Robotics, Inc. to Present at the 2015 Leerink Global Healthcare Conference

Waltham, MA – February 6, 2015 – [Corindus Vascular Robotics, Inc. \[OTCQB: CVRS\]](#), a leading developer of precision vascular robotics, announced today that its CEO, David M. Handler, will present at the 2015 Leerink Global Healthcare Conference on February 11 at 8:50am EST at The Waldorf Astoria Hotel in New York City.

About Corindus Vascular Robotics, Inc.

[Corindus Vascular Robotics, Inc.](#) is a global technology leader in robotic-assisted percutaneous coronary interventions (PCIs). The company's FDA-cleared CorPath 200 System is the first medical device that offers interventional cardiologists PCI procedure control from a radiation protective interventional cockpit. With the CorPath System, Corindus Vascular Robotics brings robotic precision to PCI procedures to help optimize clinical outcomes and minimize the costs associated with complications through improper stent placement. Corindus stands behind its product with its unique \$1,000 hospital credit "One Stent Program." For additional information, visit www.corindus.com, and follow @CorindusInc.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy securities of Corindus Vascular Robotics, Inc. (the "Company"). Certain statements in this release, including the health hazards tied to interventional cardiology, the reduction in radiation resulting from the use of the CorPath System, the PCI procedure control from the interventional cockpit, the optimization of clinical outcomes and the minimization of costs associated with complications through improper stent placement, and other written or oral statements made by or on behalf of the Company are "forward-looking statements" within the meaning of the federal securities laws. Statements regarding future events and developments and our future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future are forward-looking statements within the meaning of these laws. The forward-looking statements are subject to a number of risks and uncertainties including FDA and market acceptance of the Company's products and the Company's continued access to capital and other risks and uncertainties identified in the Company's Current Report on Form 8-K/A, Amendment No. 1, filed with the Securities and Exchange Commission (SEC) on August 15, 2014 and the Company's Registration Statement on Form S-1, Amendment No. 4, filed with the SEC on January 14, 2015. The actual results the Company achieves may differ materially from any forward-looking statements due to such risks and uncertainties. These statements are based on our current expectations and speak only as of the date of such statements. The Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of future events, new information or otherwise.

###

Media Contacts:

Corindus Vascular Robotics
Brett Prince
(508) 653-3335 ext. 231
brett.prince@corindus.com

Sourav Das
203-504-8230 ext. 131
corindus@knbpr.com